The challenge is to assess changes assuming the worst possible outcome

August 2, 2022 Podcast

This is a preview of subscriber content

Subscribe now to continue reading.

The contentious 'catch-up' price reductions, the wording of industry agreements, the 'clever but consistent' policy approach, the real risk of other 'surprises' and the discomfort of having to defend federal government officials. …

Subscribe now to continue reading.

Latest Video

Australian study finds maternal RSV vaccination offers strong protection for infants
August 25, 2026 - Latest News
July recommendations across oncology, rare disease and chronic care
August 24, 2026 - Latest News
Avecho moves to deepen global partnering push as CBD insomnia program advances
August 24, 2026 - Australian Biotech
These rarely stated realities should be discussed in the open more often
August 24, 2026 - Latest News
Acrux brings experienced clinical leader aboard to advance testosterone program
August 24, 2026 - Australian Biotech

The challenge is to assess changes assuming the worst possible outcome

This is a preview of subscriber content

Latest Video

Most Read

Australian study finds maternal RSV vaccination offers strong protection for infants

July recommendations across oncology, rare disease and chronic care

Avecho moves to deepen global partnering push as CBD insomnia program advances

These rarely stated realities should be discussed in the open more often

Acrux brings experienced clinical leader aboard to advance testosterone program

New Stories

Noxopharm pushes Sofra platform towards cancer proof of concept

Argent BioPharma takes CannEpil into US veterinary regulatory process

Entropy takes TRP-8803 to the US in head-to-head depression trial

Neuren’s first dividend signals a new phase built on DAYBUE royalties

Starpharma narrows loss as Genentech deal lifts revenue and new funding extends runway

Genetic Signatures and Microba explore merger to build infectious disease diagnostics group

Australian company secures European approval for rare disease treatment

Sign In

The challenge is to assess changes assuming the worst possible outcome

This is a preview of subscriber content

Latest Video

Most Read

Australian study finds maternal RSV vaccination offers strong protection for infants

July recommendations across oncology, rare disease and chronic care

Avecho moves to deepen global partnering push as CBD insomnia program advances

These rarely stated realities should be discussed in the open more often

Acrux brings experienced clinical leader aboard to advance testosterone program

Follow Us

New Stories

Noxopharm pushes Sofra platform towards cancer proof of concept

Argent BioPharma takes CannEpil into US veterinary regulatory process

Entropy takes TRP-8803 to the US in head-to-head depression trial

Neuren’s first dividend signals a new phase built on DAYBUE royalties

Starpharma narrows loss as Genentech deal lifts revenue and new funding extends runway

Genetic Signatures and Microba explore merger to build infectious disease diagnostics group

Australian company secures European approval for rare disease treatment